期刊
STEM CELLS
卷 29, 期 11, 页码 1650-1655出版社
WILEY
DOI: 10.1002/stem.745
关键词
Stem/progenitor cell; Cell therapy; Ischemia; Angiogenesis; Regeneration
资金
- Riken Center for Developmental Biology, Kobe [08001475]
- Grants-in-Aid for Scientific Research [22590796] Funding Source: KAKEN
Endothelial progenitor cells (EPCs) have been isolated and shown to be effective in animal models of ischemia, and many groups involved in clinical trials have demonstrated that EPC therapy is safe and feasible for the treatment of critical limb ischemia and cardiovascular diseases. However, many issues in the field of EPC biology, especially in regards to the proper and unambiguous molecular characterization of these cells still remain unresolved, hampering not only basic research but also the effective therapeutic use and widespread application of these cells. In this review, we introduce the recent concept of EPC identification in terms of hematopoietic and non-hematopoietic EPCs along with the development of EPC biology research. Furthermore, we define the role of circulating EPCs in postnatal neovascularization to illustrate the future direction of EPC therapeutic applications. Next, we review on-going medical applications of EPC for cardiovascular and peripheral vascular diseases, introduce the practical example of therapeutic application of EPCs to patients with ischemic disease, and discuss about the feedback of clinical researches. STEM CELLS 2011;29:1650-1655
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据